Eloxx Pharmaceuticals (NASDAQ:ELOX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) to a hold rating in a report issued on Saturday.

A number of other analysts have also recently commented on the stock. Lifesci Capital began coverage on shares of Eloxx Pharmaceuticals in a research note on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 target price for the company. Guggenheim assumed coverage on shares of Eloxx Pharmaceuticals in a research note on Monday, July 20th. They issued a “buy” rating and a $43.00 price target on the stock. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $41.50.

Eloxx Pharmaceuticals Price Performance

NASDAQ:ELOX opened at $17.43 on Friday. The business’s fifty day moving average is $16.60. The firm has a market capitalization of $11.99 million, a PE ratio of -1.14 and a beta of -1,891.27. Eloxx Pharmaceuticals has a fifty-two week low of $13.79 and a fifty-two week high of $18.42.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.